- Report
- March 2024
- 898 Pages
Global
From €5332EUR$5,600USD£4,557GBP
- Report
- January 2024
- 285 Pages
Global
From €9045EUR$9,500USD£7,731GBP
- Report
- May 2018
- 204 Pages
Global
From €2236EUR$2,349USD£1,912GBP
- Clinical Trials
- January 2020
- 500 Pages
Global
From €2285EUR$2,400USD£1,953GBP
- Report
- June 2018
- 15 Pages
Global
From €9521EUR$10,000USD£8,138GBP
Xadago is a market within the context of Central Nervous System (CNS) drugs. It is a type of drug used to treat Parkinson's disease, a neurological disorder that affects movement. Xadago is a monoamine oxidase type B (MAO-B) inhibitor, which works by blocking the breakdown of dopamine in the brain. This helps to improve the symptoms of Parkinson's disease, such as tremors, stiffness, and difficulty with movement. Xadago is also used to treat depression and anxiety.
The Xadago market is made up of a variety of companies, including Merck, Teva Pharmaceuticals, and Lundbeck. These companies produce and distribute Xadago, as well as other CNS drugs. They also provide support and resources to patients and healthcare professionals. Additionally, there are a number of research organizations and clinical trials that are dedicated to studying the effects of Xadago and other CNS drugs. Show Less Read more